Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01106014




Registration number
NCT01106014
Ethics application status
Date submitted
2/04/2010
Date registered
19/04/2010
Date last updated
11/01/2018

Titles & IDs
Public title
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
Scientific title
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Secondary ID [1] 0 0
AC-065A302
Universal Trial Number (UTN)
Trial acronym
GRIPHON
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pulmonary Arterial Hypertension 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders
Cardiovascular 0 0 0 0
Hypertension

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Selexipag
Treatment: Drugs - Placebo

Experimental: 1 - Selexipag is up-titrated from Day 1 to Week 12 to each patient's maximum tolerated dose in the range of 200-1600 µg twice a day (b.i.d.) in 200 µg steps starting with one 200 µg oral tablet on Day 1. From Day 2 onwards, a b.i.d. dose regimen with an interval of approximately 12 hours is followed. If this dose (selexipag 200 µg b.i.d.) is well-tolerated, selexipag is up-titrated with weekly increments of 200 µg. Up-titration is followed by a stable maintenance treatment period from Week 12 onwards, up to Week 26, at the maximum tolerated dose

Placebo Comparator: 2 - Matching placebo is administered orally with a dosing interval of approximately12 h. A (mock) up-titration scheme is followed


Treatment: Drugs: Selexipag
Selexipag 200 µg tablets

Treatment: Drugs: Placebo
Placebo tablets matching selexipag
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time From Randomization to the First Morbidity Event or Death (All Causes) up to 7 Days After the Last Study Drug Intake
Timepoint [1] 0 0
Up to 7 days after end of double-blind treatment (maximum: 4.3 years)
Secondary outcome [1] 0 0
Change From Baseline to Week 26 in 6-minute Walk Distance (6MWD) at Trough
Timepoint [1] 0 0
Week 26
Secondary outcome [2] 0 0
Absence of Worsening From Baseline to Week 26 in Modified NYHA/WHO Functional Class (WHO FC)
Timepoint [2] 0 0
Week 26

Eligibility
Key inclusion criteria
- Male and female patients 18-75 years old, with symptomatic PAH

- PAH belonging to the following subgroups of the updated Dana Point Clinical
Classification Group 1 (Idiopathic, or Heritable, or Drug or toxin induced, or
Associated (APAH) with Connective tissue disease, Congenital heart disease with simple
systemic-to-pulmonary shunt at least 1 year after surgical repair, or HIV infection)

- Documented hemodynamic diagnosis of PAH by right heart catheterization, performed at
any time prior to Screening

- Six minute walk distance (6MWD) between 50 and 450 m at Screening within 2 weeks prior
to the Baseline Visit

- Signed informed consent
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Patients with pulmonary hypertension (PH) in the Updated Dana Point Classification
Groups 2-5, and PAH Group 1 subgroups that are not covered by the inclusion criteria

- Patients who have received prostacyclin or its analogs within 1 month before Baseline
Visit, or are scheduled to receive any of these compounds during the trial

- Patients with moderate or severe obstructive lung disease

- Patients with moderate or severe restrictive lung disease

- Patients with moderate or severe hepatic impairment (Child-Pugh B and C)

- Patients with documented left ventricular dysfunction

- Patients with severe renal insufficiency

- Patients with BMI <18.5 Kg/m2

- Patients who are receiving or have been receiving any investigational drugs within 1
month before the Baseline Visit

- Acute or chronic impairment (other than dyspnea), limiting the ability to comply with
study requirements, in particular with 6MWT

- Recently conducted or planned cardio-pulmonary rehabilitation program based on
exercise training

- Psychotic, addictive or other disorder limiting the ability to provide informed
consent or to comply with study requirements

- Life expectancy less than 12 months

- Females who are lactating or pregnant or plan to become pregnant during the study

- Known hypersensitivity to any of the excipients of the drug formulations

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/12/2009
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/10/2014
Sample size
Target
Accrual to date
Final
1156
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Recruitment hospital [1] 0 0
St. Vincent's Hospital / Heart and Lung Transplant Unit - Darlinghurst
Recruitment hospital [2] 0 0
Prince Charles Hospital Lung Transplant, Thoracic Department - Chermside
Recruitment hospital [3] 0 0
Royal Adelaide Hospital, Cardiovascular Investigation Unit (CVIU) - Adelaide
Recruitment hospital [4] 0 0
Flinders Medical Centre, Pulmonary Hypertension, c/- Cardiology - Bedford Park
Recruitment hospital [5] 0 0
St Vincent's Hospital - Fitzroy
Recruitment hospital [6] 0 0
Royal Hobart Hospital, Centre for Clinical Research - Hobart
Recruitment hospital [7] 0 0
John Hunter Hospital Autoimmune Resource and Research Centre - New Lambton
Recruitment hospital [8] 0 0
Royal Melbourne Hospital, Department of Respiratory and Sleep Medicine - Parkville
Recruitment hospital [9] 0 0
Royal Perth Hospital - Perth
Recruitment postcode(s) [1] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [2] 0 0
4032 - Chermside
Recruitment postcode(s) [3] 0 0
5000 - Adelaide
Recruitment postcode(s) [4] 0 0
5042 - Bedford Park
Recruitment postcode(s) [5] 0 0
3065 - Fitzroy
Recruitment postcode(s) [6] 0 0
TAS 7000 - Hobart
Recruitment postcode(s) [7] 0 0
2305 - New Lambton
Recruitment postcode(s) [8] 0 0
VIC 3050 - Parkville
Recruitment postcode(s) [9] 0 0
6000 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Delaware
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Indiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Iowa
Country [8] 0 0
United States of America
State/province [8] 0 0
Kentucky
Country [9] 0 0
United States of America
State/province [9] 0 0
Louisiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Maryland
Country [11] 0 0
United States of America
State/province [11] 0 0
Massachusetts
Country [12] 0 0
United States of America
State/province [12] 0 0
Michigan
Country [13] 0 0
United States of America
State/province [13] 0 0
Missouri
Country [14] 0 0
United States of America
State/province [14] 0 0
New Jersey
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
North Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Ohio
Country [18] 0 0
United States of America
State/province [18] 0 0
Oregon
Country [19] 0 0
United States of America
State/province [19] 0 0
Pennsylvania
Country [20] 0 0
United States of America
State/province [20] 0 0
Tennessee
Country [21] 0 0
United States of America
State/province [21] 0 0
Texas
Country [22] 0 0
United States of America
State/province [22] 0 0
Wisconsin
Country [23] 0 0
Argentina
State/province [23] 0 0
Buenos Aires
Country [24] 0 0
Argentina
State/province [24] 0 0
Cordoba
Country [25] 0 0
Argentina
State/province [25] 0 0
Corrientes
Country [26] 0 0
Austria
State/province [26] 0 0
Graz
Country [27] 0 0
Austria
State/province [27] 0 0
Vienna
Country [28] 0 0
Belarus
State/province [28] 0 0
Minsk
Country [29] 0 0
Belgium
State/province [29] 0 0
Brussels
Country [30] 0 0
Belgium
State/province [30] 0 0
Leuven
Country [31] 0 0
Canada
State/province [31] 0 0
Alberta
Country [32] 0 0
Canada
State/province [32] 0 0
British Columbia
Country [33] 0 0
Canada
State/province [33] 0 0
Manitoba
Country [34] 0 0
Canada
State/province [34] 0 0
Ontario
Country [35] 0 0
Canada
State/province [35] 0 0
Quebec
Country [36] 0 0
Chile
State/province [36] 0 0
Santiago
Country [37] 0 0
China
State/province [37] 0 0
Beijing
Country [38] 0 0
China
State/province [38] 0 0
Guangzhou
Country [39] 0 0
China
State/province [39] 0 0
Shanghai
Country [40] 0 0
Colombia
State/province [40] 0 0
Bogota
Country [41] 0 0
Czechia
State/province [41] 0 0
Praha 2
Country [42] 0 0
Denmark
State/province [42] 0 0
Arhus
Country [43] 0 0
Denmark
State/province [43] 0 0
Copenhagen
Country [44] 0 0
France
State/province [44] 0 0
Bron cedex
Country [45] 0 0
France
State/province [45] 0 0
Caen Cedex
Country [46] 0 0
France
State/province [46] 0 0
Clamart
Country [47] 0 0
France
State/province [47] 0 0
Lille Cedex
Country [48] 0 0
France
State/province [48] 0 0
Strasbourg
Country [49] 0 0
France
State/province [49] 0 0
Toulouse Cedex 9
Country [50] 0 0
Germany
State/province [50] 0 0
Berlin
Country [51] 0 0
Germany
State/province [51] 0 0
Dresden
Country [52] 0 0
Germany
State/province [52] 0 0
Giessen
Country [53] 0 0
Germany
State/province [53] 0 0
Greifswald
Country [54] 0 0
Germany
State/province [54] 0 0
Hannover
Country [55] 0 0
Germany
State/province [55] 0 0
Heidelberg
Country [56] 0 0
Germany
State/province [56] 0 0
Köln
Country [57] 0 0
Germany
State/province [57] 0 0
Leipzig
Country [58] 0 0
Germany
State/province [58] 0 0
Löwenstein
Country [59] 0 0
Germany
State/province [59] 0 0
Regensburg
Country [60] 0 0
Greece
State/province [60] 0 0
Athens
Country [61] 0 0
Hungary
State/province [61] 0 0
Budapest
Country [62] 0 0
Hungary
State/province [62] 0 0
Debrecen
Country [63] 0 0
Hungary
State/province [63] 0 0
Pécs
Country [64] 0 0
Hungary
State/province [64] 0 0
Szeged
Country [65] 0 0
India
State/province [65] 0 0
Ahmedabad
Country [66] 0 0
India
State/province [66] 0 0
Chennai
Country [67] 0 0
India
State/province [67] 0 0
Hyderabad
Country [68] 0 0
India
State/province [68] 0 0
New Delhi
Country [69] 0 0
Ireland
State/province [69] 0 0
Dublin
Country [70] 0 0
Israel
State/province [70] 0 0
Haifa
Country [71] 0 0
Israel
State/province [71] 0 0
Jerusalem
Country [72] 0 0
Israel
State/province [72] 0 0
Petach Tikvah
Country [73] 0 0
Israel
State/province [73] 0 0
Rehovot
Country [74] 0 0
Israel
State/province [74] 0 0
Tel-Hashomer
Country [75] 0 0
Italy
State/province [75] 0 0
Bologna
Country [76] 0 0
Italy
State/province [76] 0 0
Napoli
Country [77] 0 0
Italy
State/province [77] 0 0
Palermo
Country [78] 0 0
Korea, Republic of
State/province [78] 0 0
Incheon
Country [79] 0 0
Korea, Republic of
State/province [79] 0 0
Seoul
Country [80] 0 0
Malaysia
State/province [80] 0 0
Kuala Lumpur
Country [81] 0 0
Mexico
State/province [81] 0 0
Mexico City
Country [82] 0 0
Netherlands
State/province [82] 0 0
Amsterdam
Country [83] 0 0
Netherlands
State/province [83] 0 0
Maastricht
Country [84] 0 0
Netherlands
State/province [84] 0 0
Nieuwegein
Country [85] 0 0
Netherlands
State/province [85] 0 0
Rotterdam
Country [86] 0 0
Peru
State/province [86] 0 0
Lima
Country [87] 0 0
Poland
State/province [87] 0 0
Gdansk
Country [88] 0 0
Poland
State/province [88] 0 0
Krakow
Country [89] 0 0
Poland
State/province [89] 0 0
Warszawa
Country [90] 0 0
Poland
State/province [90] 0 0
Lódz
Country [91] 0 0
Romania
State/province [91] 0 0
Bucharest
Country [92] 0 0
Romania
State/province [92] 0 0
Iasi
Country [93] 0 0
Russian Federation
State/province [93] 0 0
Barnaul
Country [94] 0 0
Russian Federation
State/province [94] 0 0
Ekaterinburg
Country [95] 0 0
Russian Federation
State/province [95] 0 0
Kemerovo
Country [96] 0 0
Russian Federation
State/province [96] 0 0
Moscow
Country [97] 0 0
Russian Federation
State/province [97] 0 0
Novosibirsk
Country [98] 0 0
Russian Federation
State/province [98] 0 0
St Petersburg
Country [99] 0 0
Russian Federation
State/province [99] 0 0
Tomsk
Country [100] 0 0
Serbia
State/province [100] 0 0
Belgrade
Country [101] 0 0
Singapore
State/province [101] 0 0
Singapore
Country [102] 0 0
Slovakia
State/province [102] 0 0
Bratislava
Country [103] 0 0
Spain
State/province [103] 0 0
Barcelona
Country [104] 0 0
Spain
State/province [104] 0 0
Madrid
Country [105] 0 0
Sweden
State/province [105] 0 0
Goteborg
Country [106] 0 0
Sweden
State/province [106] 0 0
Linköping
Country [107] 0 0
Sweden
State/province [107] 0 0
Umea
Country [108] 0 0
Sweden
State/province [108] 0 0
Uppsala
Country [109] 0 0
Switzerland
State/province [109] 0 0
Basel
Country [110] 0 0
Switzerland
State/province [110] 0 0
Bern
Country [111] 0 0
Switzerland
State/province [111] 0 0
Genève 14
Country [112] 0 0
Switzerland
State/province [112] 0 0
St. Gallen
Country [113] 0 0
Taiwan
State/province [113] 0 0
Kaohsiung
Country [114] 0 0
Taiwan
State/province [114] 0 0
Taipei
Country [115] 0 0
Thailand
State/province [115] 0 0
Khon Kaen
Country [116] 0 0
Turkey
State/province [116] 0 0
Adana
Country [117] 0 0
Turkey
State/province [117] 0 0
Istanbul
Country [118] 0 0
Turkey
State/province [118] 0 0
Izmir
Country [119] 0 0
Ukraine
State/province [119] 0 0
Dnipropetrovsk
Country [120] 0 0
Ukraine
State/province [120] 0 0
Kharkiv
Country [121] 0 0
Ukraine
State/province [121] 0 0
Kyiv
Country [122] 0 0
Ukraine
State/province [122] 0 0
Lviv
Country [123] 0 0
United Kingdom
State/province [123] 0 0
Glasgow
Country [124] 0 0
United Kingdom
State/province [124] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Actelion
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The AC-065A302 (GRIPHON) study is an event-driven Phase 3 study to demonstrate the effect of
selexipag on time to first morbidity or mortality event in patients with pulmonary arterial
hypertension.
Trial website
https://clinicaltrials.gov/ct2/show/NCT01106014
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Aline Frey
Address 0 0
Actelion
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/ct2/show/NCT01106014